

The **GROUP**: GC-08 “Hormonas y cancer”

Look for **CANDIDATES** to apply to **MINECO** Program “**JUAN DE LA CIERVA**” (December 9th 2015)

POSTDOCTORAL CONTRACT

Place: Maimonides Biomedical Research Institute of Cordoba (IMIBIC)

Link of Group: <http://www.imibic.org/site/grupo/15/gc-08-hormonas-y-cancer>

Topic: The group is interested in exploring the cellular and molecular basis underlying the processes of neuroendocrine and metabolic regulation as well as its dysfunction in tumoral pathologies and cancer, paying special attention to the role exerted by some endocrine regulators such as the somatostatin and ghrelin systems. The studies have led to the discovery and characterization of new receptors, functions and mechanisms of action for different neuro-endocrine-metabolic signals that play a pivotal role in the hormonal secretion, tumorigenesis and cell survival of different normal and tumoral cells, with the final aim to contribute to the future design of innovative therapeutic strategies. During the last years, the group has broadened and consolidated its capacity to implement innovative technologies in the study of cellular and molecular Endocrinology and Oncology, through the adaptation on previous techniques and the incorporation of novel methodologies and experimental models.

Number of total of publications of group (last 7 years): More than 70

Recent publications:

Luque RM, Sampedro-Núñez M, Gahete MD, Ramos-Levi A, Ibáñez-Costa A, Rivero-Cortés E, Serrano-Somavilla A, Adrados M, Culler MD, Castaño JP, Marazuela M. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters. *Oncotarget*. 2015; 6(23):19619-33.

Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. *Cancer Lett*. 2015; 359(2):299-306.

Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. *Oncotarget*. 2015

Ibáñez-Costa A, Gahete MD, Rivero-Cortés E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA, Venegas-Moreno E, Gálvez MÁ, García-Arnés JA, Soto-Moreno A, Morgan J, Tsomaia N, Culler MD, Dieguez C, Castaño JP, Luque RM. In1-ghrelin splicing variant is

overexpressed in pituitary adenomas and increases their aggressive features. Sci Rep. 2015; 5:8714

Gahete MD, Córdoba-Chacón J, Lantvit DD, Ortega-Salas R, Sanchez-Sanchez R, Pérez-Jiménez F, López-Miranda J, Swanson SM, Castaño JP, Luque RM, Kineman RD. Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice. Carcinogenesis. 2014; 35(11):2467-73

BOE: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2015-13308

Candidates' requirements:

-Modality "JdC-FORMACIÓN" (external to Córdoba): see BOE.

Publications as first author in high impact factor journals (D1 and Q1) will be positively evaluated.

-Modality "JdC-INCORPORACIÓN": see BOE.

Publications as first and/or corresponding author in high impact factor journals (D1 and Q1) will be positively evaluated.

In any case, publications on peer-reviewed journals are required, and experience on molecular and cellular techniques applied to biomedical research, especially in the Oncology and/or Endocrinology fields will be evaluated.

Send CV to: raul.luque@uco.es